Abbott India Limited, a leading multinational pharmaceutical powerhouse, has announced a final dividend of ₹475 per equity share for the financial year ended March 31, 2025. This hefty payout, subject to shareholder approval at the 81st Annual General Meeting (AGM) on August 13, 2025.
Key Dividend Details:
Through an exchange filing on 15 May 2025, Abbott India Limited has declared a final dividend of ₹475 per equity share (on a face value of ₹10) for the financial year ended March 31, 2025. This dividend equals 4 750 % of the face value.
The company has set July 25, 2025, as the Record Date for determining
entitlement of Members to Final Dividend. The shares will start trading ex-dividend on July 24..
To be eligible for this payout, shareholders must ensure their names are registered in the company’s records or reflected as beneficial owners with depositories like NSDL/CDSL by the record date of July 25, 2025.
The dividend will be paid on or after August 18, 2025, following formal approval at the upcoming Annual General Meeting (AGM) scheduled for August 13, 2025.
The dividend yield stands at 1.36%.
Also Read – This “Chaddi” Making Company Declares a ₹200 Dividend
Abbott India Dividend History
| Ex-Date | Dividend Type | Amount (₹/share) |
|---|---|---|
| 19-07-2024 | Final Dividend | 410.00 |
| 21-07-2023 | Special Dividend | 145.00 |
| 21-07-2023 | Final Dividend | 180.00 |
| 02-08-2022 | Final Dividend | 145.00 |
| 02-08-2022 | Special Dividend | 130.00 |
Abbott India announces its highest-ever final dividend of ₹475/share for FY25, surpassing 2024’s ₹410. Earlier payouts include ₹325/share (2023: ₹145 special + ₹180 final) and ₹275/share (2022: ₹130 special + ₹145 final).
With a market capitalisation of around ₹64,500 Crores, the shares of Abbott India are currently trading at a P/E of around 48 which is almost equal to the industry average.
The company came up with good numbers in its Q4 FY2025 results. It reported a net profit of ₹367 crore, which is a 28% increase. It also reported an 11.5% increase in revenue.
Company Overview
| Company Name | Abbott India Limited |
| Stock Exchange | BSE, NSE |
| Market Cap | ₹64,500 crore (approx. May 2025) |
| Parent Company | Abbott Laboratories, USA (founded by Dr. Wallace C. Abbott in 1888) |
| Incorporation | 1944 |
| Headquarters | Mumbai, Maharashtra, India |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
Also Read – Tata Elxsi Announces Record Date for Dividend
Established in 1944 as a subsidiary of Abbott Laboratories (USA), Abbott India is a leader in the Indian Pharmaceutical Market (IPM), with 7 brands in the IPM’s Top 100 and 12 brands dominating their therapeutic categories. The company drives innovation, launching 8 new products in FY24.
While primarily focused on India, the company also serves neighboring markets like Sri Lanka, Nepal, and Bhutan, with exports contributing 2% to annual revenues.
Disclaimer:
This article is for informational and educational purposes only. It does not constitute financial advice. The author is not a registered financial advisor. While the content is written in good faith and with the utmost care, complete accuracy is not guaranteed. However, updates and corrections will be made as needed to ensure current and correct information.